Cargando…

Metabolic reprogramming of pulmonary fibrosis

Pulmonary fibrosis is a progressive and intractable lung disease with fibrotic features that affects alveoli elasticity, which leading to higher rates of hospitalization and mortality worldwide. Pulmonary fibrosis is initiated by repetitive localized micro-damages of the alveolar epithelium, which s...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiaxin, Zhai, Xiaoxuan, Sun, Xiao, Cao, Shengchuan, Yuan, Qiuhuan, Wang, Jiali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702072/
https://www.ncbi.nlm.nih.gov/pubmed/36452229
http://dx.doi.org/10.3389/fphar.2022.1031890
_version_ 1784839653995577344
author Li, Jiaxin
Zhai, Xiaoxuan
Sun, Xiao
Cao, Shengchuan
Yuan, Qiuhuan
Wang, Jiali
author_facet Li, Jiaxin
Zhai, Xiaoxuan
Sun, Xiao
Cao, Shengchuan
Yuan, Qiuhuan
Wang, Jiali
author_sort Li, Jiaxin
collection PubMed
description Pulmonary fibrosis is a progressive and intractable lung disease with fibrotic features that affects alveoli elasticity, which leading to higher rates of hospitalization and mortality worldwide. Pulmonary fibrosis is initiated by repetitive localized micro-damages of the alveolar epithelium, which subsequently triggers aberrant epithelial-fibroblast communication and myofibroblasts production in the extracellular matrix, resulting in massive extracellular matrix accumulation and interstitial remodeling. The major cell types responsible for pulmonary fibrosis are myofibroblasts, alveolar epithelial cells, macrophages, and endothelial cells. Recent studies have demonstrated that metabolic reprogramming or dysregulation of these cells exerts their profibrotic role via affecting pathological mechanisms such as autophagy, apoptosis, aging, and inflammatory responses, which ultimately contributes to the development of pulmonary fibrosis. This review summarizes recent findings on metabolic reprogramming that occur in the aforementioned cells during pulmonary fibrosis, especially those associated with glucose, lipid, and amino acid metabolism, with the aim of identifying novel treatment targets for pulmonary fibrosis.
format Online
Article
Text
id pubmed-9702072
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97020722022-11-29 Metabolic reprogramming of pulmonary fibrosis Li, Jiaxin Zhai, Xiaoxuan Sun, Xiao Cao, Shengchuan Yuan, Qiuhuan Wang, Jiali Front Pharmacol Pharmacology Pulmonary fibrosis is a progressive and intractable lung disease with fibrotic features that affects alveoli elasticity, which leading to higher rates of hospitalization and mortality worldwide. Pulmonary fibrosis is initiated by repetitive localized micro-damages of the alveolar epithelium, which subsequently triggers aberrant epithelial-fibroblast communication and myofibroblasts production in the extracellular matrix, resulting in massive extracellular matrix accumulation and interstitial remodeling. The major cell types responsible for pulmonary fibrosis are myofibroblasts, alveolar epithelial cells, macrophages, and endothelial cells. Recent studies have demonstrated that metabolic reprogramming or dysregulation of these cells exerts their profibrotic role via affecting pathological mechanisms such as autophagy, apoptosis, aging, and inflammatory responses, which ultimately contributes to the development of pulmonary fibrosis. This review summarizes recent findings on metabolic reprogramming that occur in the aforementioned cells during pulmonary fibrosis, especially those associated with glucose, lipid, and amino acid metabolism, with the aim of identifying novel treatment targets for pulmonary fibrosis. Frontiers Media S.A. 2022-11-14 /pmc/articles/PMC9702072/ /pubmed/36452229 http://dx.doi.org/10.3389/fphar.2022.1031890 Text en Copyright © 2022 Li, Zhai, Sun, Cao, Yuan and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Jiaxin
Zhai, Xiaoxuan
Sun, Xiao
Cao, Shengchuan
Yuan, Qiuhuan
Wang, Jiali
Metabolic reprogramming of pulmonary fibrosis
title Metabolic reprogramming of pulmonary fibrosis
title_full Metabolic reprogramming of pulmonary fibrosis
title_fullStr Metabolic reprogramming of pulmonary fibrosis
title_full_unstemmed Metabolic reprogramming of pulmonary fibrosis
title_short Metabolic reprogramming of pulmonary fibrosis
title_sort metabolic reprogramming of pulmonary fibrosis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702072/
https://www.ncbi.nlm.nih.gov/pubmed/36452229
http://dx.doi.org/10.3389/fphar.2022.1031890
work_keys_str_mv AT lijiaxin metabolicreprogrammingofpulmonaryfibrosis
AT zhaixiaoxuan metabolicreprogrammingofpulmonaryfibrosis
AT sunxiao metabolicreprogrammingofpulmonaryfibrosis
AT caoshengchuan metabolicreprogrammingofpulmonaryfibrosis
AT yuanqiuhuan metabolicreprogrammingofpulmonaryfibrosis
AT wangjiali metabolicreprogrammingofpulmonaryfibrosis